Votoplam Advances to Phase 3: Novartis and PTC Chart Measured Path for Huntington’s Disease Treatment
Novartis and PTC Therapeutics have advanced their Huntington's disease candidate, votoplam, into Phase 3 development following promising mid-stage results. The decision reflects confidence in the program's potential while signaling caution…
Continue Reading
Votoplam Advances to Phase 3: Novartis and PTC Chart Measured Path for Huntington’s Disease Treatment
